Ribo granted EMA Orphan Drug Designation for siRNA therapeutic RBD1016 for hepatitis delta Virus (HDV) Infection

BEIJING, China & GOTHENBURG, Sweden — 2025-10-24 — Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo), today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to RBD1016 for…

Continue Reading